Invest In Harmonic Health

The Future of Physics Medicine: Neuroscience + Precision Mechanical Stimulation

Wearable noninvasive neuromodulation gives

Power Over Pain

Harmonic Pain Solutions (a spinoff of Pain Care Labs) is an NIH-funded medical technology company leading the therapeutic M-Stim field. An array of frequencies mounted on our rigid back brace use harmonic complexity to target spine, nerve, or muscle pain. Precision patient-controlled options, including heat, cold, and pressure - combine with the multi-dimensional M-stim sensation combinations. Using connectome neuroscience, neuromodulation, and local tissue therapy, DuoTherm is intended to be the first device FDA-indicated and CMS-covered for opioid reduction.

Reasons to Invest

World-class team with combined 60+ years of medical device experience: led by scientist-entrepreneur and NIH pioneer in vibration pain reduction, advised by biotech consultants from City Science Center and Columbia University, with successful FDA 510(k) and ISO-13485 certs.
Phase II trial underway, Pilot reduced pain 57%: our devices are ready for distribution, awaiting the first De Novo indication for opioid use pending the completion of the acute and chronic low back pain trials NCT04491175 and NCT04494698.
Already raised $5M in non-dilutive grants for project: No previous dilution.
Established key accounts and TAM of $4.3B: 11M failed epidurals, .5M lumbar surgeries, 1M injuries covered by workers comp and 850RF ablations can be addressed with our device, replacing the braces covered at $1500 and obviating the need for opioids or even surgery.
Novel technology for unsatisfied market: The spine pain market is $122BN, with most patients seeking any option other than surgery. We have been first to market with our pain-canceling frequency for MSK pain, and have 12 issued utility patents and CIPs supporting our novel multimodal array of harmonic frequencies and thermal combinations.
Winner of National Institutes of Health SBA Tibbetts award: Our two SBIR Fast Tracks led to discoveries of the optimal combination of frequency and thermal pain relief, and the award recognizes the "economic, technical, and societal benefits of SBIR Funding". This is the same award 23&me won in 2016.

The preceding analysis should be read in conjunction with all materials included with it. This analysis contains forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Any statements that are not statements of historical fact are forward-looking statements. When used, as well as whether or not used but are implied, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect," and the like, and/or future-tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements in these materials. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors such as those included in the supporting materials provided herewith. We do not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this projection's preparation.